PRECISION ONCOLOGY PLATFORM
Every Patient with Cancer Deserves Complete Answers
No two patients are the same — and at the biological level, neither are their individual cancers. That’s why Caris goes beyond limited testing and analyzes DNA, RNA and proteins across both tissue and blood to reveal the full molecular picture.
More complete answers, more informed decisions — more personalized care.
Start with the insight you need:
The power behind precision oncology
Backed by Powerful Data
By combining and analyzing vast quantities of genomic, transcriptomic and proteomic data, Caris has created one of the largest, most comprehensive multimodal databases of molecular and clinical outcomes data in the world. This wealth of information — and the actionable insights it unlocks for healthcare providers — comprises the foundation of our ability to deliver on the promise of precision medicine by:
- Understanding your disease at a deeper level
- Identifying treatments that may work for your cancer
- Connecting you to clinical trials matched to your biology
- Supporting the development of tomorrow’s therapies
The Impact of Precision Oncology
1 Million+
Patient Cases
400,000
Human Life Years
Added in 2025
23,000+
Gene Coverage
6.5 Million+
Tests Completed
COMPREHENSIVE PROFILING SOLUTIONS
The Right Test for Your Cancer — Exactly When You Need It
Whether you start with a tissue biopsy, a blood draw, an early-stage breast cancer diagnosis or a suspected myeloid malignancy, Caris offers purpose-built profiling solutions designed to bring clarity when decisions matter most.
Sample type: Tumor tissue
MI Cancer Seek®
When you need the most complete picture from tissue
MI Cancer Seek is the #1 most-ordered comprehensive tissue-profiling test — analyzing 23,000+ genes through simultaneous Whole Exome and Whole Transcriptome Sequencing. It’s the first and only WES/WTS-based assay with FDA-approved companion diagnostic indications for adult and pediatric patients (ages 1+).
Sample type: Tumor tissue (H&E slide)
Caris MI Clarity™
Providing a clearer path forward with early-stage breast cancer
For HR+/HER2-, node-negative breast cancer, treatment decisions often come before the full picture of recurrence risk is clear. Caris MI Clarity uses AI and computational pathology (no genomic sequencing required) to stratify early and late distant recurrence risk, so you and your physician can plan with greater confidence.
Sample type: Blood
Caris Assure®
Whole Blood. Whole Picture.
Caris Assure is the only liquid biopsy that analyzes both plasma and buffy coat, helping distinguish true tumor signals from incidental findings and delivering a more complete, confident molecular profile from a simple blood draw.
Sample type: Blood / bone marrow
Caris ChromoSeq™
Myeloid cancers require efficient answers
Myeloid malignancies are complex — genetic testing doesn’t have to be. Caris ChromoSeq replaces fragmented workflows with one WGS assay, delivering a complete molecular picture in a single test to support diagnosis, risk stratification and treatment decisions.
Sample type: Tumor tissue
MI Profile® (International)
Comprehensive molecular profiling that helps guide precise and individualized treatment decisions.
Assessment of DNA, RNA and Proteins from tumor tissue to reveal a more complete molecular blueprint for clinicians to assess next steps forward in a patient’s care.
Available globally (excluding USA, EEA, EU, and CH)
Sample type: Tumor tissue
MI Tumor Seek Hybrid™ (International)
One assay that provides a comprehensive molecular blueprint that saves tissue without compromising results.
A laboratory developed test (LDT) that simultaneously captures both DNA and RNA in one assay. Results also include AI signatures to help confirm diagnosis and improve therapy selection.
Available globally (excluding USA, EEA, EU, and CH)
“Caris was built for one reason — to improve the human condition.
Through tireless efforts, breakthrough molecular science and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work: the patient.”
David Dean Halbert, DSc (h.c.)
Chairman, Founder and CEO
Real Patient Story
Knowledge is power. Testing is power.
Maggie McCloskey
Stage IV Lung Cancer Survivor
Real PHYSICIAN Story
The results of Caris testing are extremely important in how we decide the best personalized therapy for each individual patient.
Christopher Vaughn, MD
Hematology Oncology Associates of Fredericksburg, VA
WATCH VIDEO
A Better Way to Fight Cancer
Precision oncology
Evidence and Data Powering Precision Oncology
1.0M+
Cases
6.5M+
Tests
50B+
Molecular Markers Measured
13Q+
Datapoints Generated
220+
AI-Powered Interpretations
790K+
Matched Molecular & Clinical Outcomes Database
23,000
Gene Coverage (WES & WTS)
1,200+
Publications (abstracts, posters & manuscripts)
5.6M+
Digitized Slides
95+
Members Worldwide
45+
NCI-Designated Cancer Centers
1,050+
POA Publications (abstracts, posters & manuscripts)
Molecular insights can help illuminate the path ahead.
Whether you are a patient seeking answers, a physician guiding care or a partner in our mission to advance precision oncology, Caris can help you take the next step with confidence.